Results of XX Petersburg International Economic Forum
At the days of work of XX Petersburg International Economic Forum Russian and international pharma companies signed agreements on further cooperation in the field of new drugs, technology and substance transfer, drug production localization, including full cycle production.
Agreements related to support of investment projects of pharma plants in the territory of Saint Petersburg were signed. Two of them relate to intention of the city to conclude special investment contracts (SIC) with manufacturers Geropharm and Polisan, implementing investment projects of construction of pharma plants in Petersburg. Geropharm in the Pushkino industrial area implements the site investment project on insulin and insulin analog production, as well as pharmaceutical substances and drugs based on them. Polisan is performing third-stage construction works of the plant in Petersburg. The company is a manufacturer of four original drugs, and implements two localization projects using its capacities. Bayer will manufacture contrast media for CT and MRI. Pfizer will manufacture three dyslipidemia drugs for treatment of rheumatoid arthritis and an antibacterial drug of oxazolidinone class.
Besides, within the framework of the Petersburg International Economic Forum an agreement between Lilli and R-Pharm on deep localization in Russia and manufacture of Humulin ®, Humalog® and long-term insulin analog using original active pharmaceutical ingredients, while keeping good control over quality of those products.
Besides, an agreement on intentions for marketing of the investment project of construction of a new production of insulins between Novo-Nordisk and the Government of Kaluga region. In the next years at the territory of the Kaluga site of the company a facility for assembly of prefilled pens FlexPenÒ will be constructed.